{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7260,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-faf2-735b-82de-3ea74fc3e6b1",
      "docSlug": "bdfbc33c2af8bbda0bee5bbbc0eb9638",
      "documentTitle": "Houlihan Lokey | Investor Presentation Deck | 33 slides",
      "authorId": "houlihan-lokey",
      "authorName": "Houlihan Lokey",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7598534,
      "pageNumber": 31,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide uses a world map as a background watermark.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-faf2-735b-82de-3ea74fc3e6b1/31",
      "deckHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1",
      "deckAnchorHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 32,
          "from": 31,
          "beatId": "ad80483e-e9e5-417f-a9b4-f053c6da5efe",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "The final slides highlight the company's mission and values.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-faf2-735b-82de-3ea74fc3e6b1",
      "docSlug": "bdfbc33c2af8bbda0bee5bbbc0eb9638",
      "documentTitle": "Houlihan Lokey | Investor Presentation Deck | 33 slides",
      "authorId": "houlihan-lokey",
      "authorName": "Houlihan Lokey",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7598534,
      "pageNumber": 32,
      "slideType": "mission",
      "function": "inspire_vision",
      "notes": "The slide uses a geometric design with two overlapping triangles to separate the vision and mission text.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-faf2-735b-82de-3ea74fc3e6b1/32",
      "deckHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1",
      "deckAnchorHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 32,
          "from": 31,
          "beatId": "ad80483e-e9e5-417f-a9b4-f053c6da5efe",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "The final slides highlight the company's mission and values.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-faf2-735b-82de-3ea74fc3e6b1",
      "docSlug": "bdfbc33c2af8bbda0bee5bbbc0eb9638",
      "documentTitle": "Houlihan Lokey | Investor Presentation Deck | 33 slides",
      "authorId": "houlihan-lokey",
      "authorName": "Houlihan Lokey",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7598534,
      "pageNumber": 33,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-faf2-735b-82de-3ea74fc3e6b1/33",
      "deckHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1",
      "deckAnchorHref": "/decks/019de075-faf2-735b-82de-3ea74fc3e6b1#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Includes date and ticker symbol.",
      "imagePath": "https://imgproxy.kitesheet.com/KhoSKt5dCgxA73wGzQWOYgitnksYcTgzjEIVQO7N4Kw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTllYzlhYTkwYjY0MGY3OWZmNzNjMjIwYjIwZmY3ZC9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/1",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "fae703f1-cd28-4418-a866-19da2c878be2",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Hook",
          "beatSlug": "hook",
          "evidence": "The cover slide and executive summary grab the audience's attention.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": "https://imgproxy.kitesheet.com/RKyFqjx2xMgNfgk9svDv8MP8Na2BYvvQfRf0swZgT1c/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTllYzlhYTkwYjY0MGY3OWZmNzNjMjIwYjIwZmY3ZC9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/z22wul-ieDTPdvuchD5xikUwLsKcSDCKR07aK4UNKS8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTllYzlhYTkwYjY0MGY3OWZmNzNjMjIwYjIwZmY3ZC9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/k_80T3dRkDJRTZyoS-9Iqwya8VXRVOrwjauBcTdGxdE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTllYzlhYTkwYjY0MGY3OWZmNzNjMjIwYjIwZmY3ZC9wMDAxLnBuZw"
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/2",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "fae703f1-cd28-4418-a866-19da2c878be2",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Hook",
          "beatSlug": "hook",
          "evidence": "The cover slide and executive summary grab the audience's attention.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide uses a numbered list format to present key value propositions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/3",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 1,
          "beatId": "fae703f1-cd28-4418-a866-19da2c878be2",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Hook",
          "beatSlug": "hook",
          "evidence": "The cover slide and executive summary grab the audience's attention.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "pain_points",
      "function": "frame_problem",
      "notes": "Uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative impacts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/4",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-4",
      "loopMatches": [
        {
          "to": 5,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2ffc44d-9434-45d1-bdb5-742ff661b2cb",
          "evidence": "The pain points slide highlights the limitations of current CAR-T therapies.",
          "position": 0,
          "objective": "What is the cost of not adopting a safer CAR-T therapy?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.8,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 4,
          "beatId": "a9c2740d-95c0-4966-afab-fd07593c2381",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Problem (Identify pain)",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "The pain points and solution slides highlight the problem and the solution.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a cartoon mascot at the bottom.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/5",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-5",
      "loopMatches": [
        {
          "to": 5,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2ffc44d-9434-45d1-bdb5-742ff661b2cb",
          "evidence": "The pain points slide highlights the limitations of current CAR-T therapies.",
          "position": 0,
          "objective": "What is the cost of not adopting a safer CAR-T therapy?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.8,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 4,
          "beatId": "a9c2740d-95c0-4966-afab-fd07593c2381",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Problem (Identify pain)",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "The pain points and solution slides highlight the problem and the solution.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/6",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-6",
      "loopMatches": [
        {
          "to": 10,
          "from": 6,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
          "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
          "position": 1,
          "objective": "Why is NXC-201 a better solution?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.8,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Uses icon-based visualization to represent market expansion from 5% of hospitals to a much broader network.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/7",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-7",
      "loopMatches": [
        {
          "to": 10,
          "from": 6,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
          "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
          "position": 1,
          "objective": "Why is NXC-201 a better solution?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.8,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "unfair_advantage",
      "function": "present_solution",
      "notes": "The slide highlights the structural difference of the NXC-201 molecule compared to Abecma, Carvykti, and CART-ddBCMA.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/8",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-8",
      "loopMatches": [
        {
          "to": 10,
          "from": 6,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
          "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
          "position": 1,
          "objective": "Why is NXC-201 a better solution?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.8,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes comparative bar charts and flow cytometry data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/9",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-9",
      "loopMatches": [
        {
          "to": 10,
          "from": 6,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
          "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
          "position": 1,
          "objective": "Why is NXC-201 a better solution?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.8,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/10",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-10",
      "loopMatches": [
        {
          "to": 10,
          "from": 6,
          "name": "Golden Circle",
          "slug": "11-golden-circle",
          "bestFor": "Visionary leadership, brand positioning, mission statements",
          "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
          "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
          "position": 1,
          "objective": "Why is NXC-201 a better solution?",
          "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
          "confidence": 0.8,
          "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/11",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-11",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a process flow diagram to illustrate the disease mechanism and a human anatomy diagram to show clinical manifestations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/12",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-12",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/13",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-13",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/14",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-14",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/15",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-15",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes a footer citing FDA approval precedents for similar single-arm studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/16",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-16",
      "loopMatches": [
        {
          "to": 16,
          "from": 11,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 2,
          "objective": "How does NXC-201 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.8,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 11,
          "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "Includes detailed clinical trial references in the footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/17",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-17",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a two-column layout to track progress for two distinct drug programs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/18",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-18",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/19",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-19",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a standard pharmaceutical pipeline table format.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/20",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-20",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/21",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-21",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a wave-like visual to represent market size, with specific dollar amounts associated with different disease categories.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/22",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-22",
      "loopMatches": [
        {
          "to": 22,
          "from": 17,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "599f547a-a204-4d5c-892f-e80629eed470",
          "evidence": "The market sizing and potential slides highlight the growing opportunity.",
          "position": 3,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.8,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 17,
          "beatId": "411eee51-0cdb-4cef-ae47-4b4cf31a0602",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Visualization",
          "beatSlug": "monroes-sequence-visualization",
          "evidence": "The market sizing and potential slides help visualize the opportunity.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "transition",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/23",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 28,
          "from": 23,
          "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/24",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 28,
          "from": 23,
          "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/25",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 28,
          "from": 23,
          "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/26",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 28,
          "from": 23,
          "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
      "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/27",
      "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
      "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 28,
          "from": 23,
          "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Desire",
          "beatSlug": "aida-desire",
          "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}